NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Ascending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
83774-0101-12 | 83774-0101 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb. 27, 2024 | In Use | |
69539-0319-05 | 69539-0319 | Abiraterone acetate | Abiraterone | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 26, 2024 | In Use | |
69539-0319-60 | 69539-0319 | Abiraterone acetate | Abiraterone | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 26, 2024 | In Use | |
70518-0916-00 | 70518-0916 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Dec. 20, 2017 | In Use | |
70518-0916-01 | 70518-0916 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Dec. 18, 2019 | In Use | |
00310-4611-50 | 00310-4611 | Durvalumab | Imfinzi | 500.0 mg/10mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 1, 2017 | In Use | |
76310-0017-50 | 76310-0017 | Amifostine | Ethyol | 500.0 mg/10mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Jan. 1, 2020 | In Use | |
55390-0308-03 | 55390-0308 | Amifostine | Amifostine | 500.0 mg/10mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | April 2, 2008 | Dec. 31, 2018 | No Longer Used |
66220-0017-03 | 66220-0017 | Amifostine | Ethyol | 500.0 mg/10mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Aug. 1, 2016 | Oct. 31, 2020 | No Longer Used |
68152-0108-09 | 68152-0108 | Belinostat | Beleodaq | 500.0 mg/10mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | July 21, 2014 | Nov. 30, 2022 | In Use |
55150-0270-01 | 55150-0270 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/2.5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Aug. 25, 2021 | In Use | |
55150-0270-99 | 55150-0270 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/2.5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Nov. 20, 2023 | In Use | |
00409-2188-01 | 00409-2188 | PEMETREXED | PEMETREXED | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 27, 2022 | In Use | |
00781-3519-90 | 00781-3519 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 8, 2022 | In Use | |
16729-0230-11 | 16729-0230 | Pemetrexed | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
43598-0387-11 | 43598-0387 | Pemetrexed disodium | Pemetrexed disodium | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
50742-0341-01 | 50742-0341 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 24, 2022 | In Use | |
55150-0382-01 | 55150-0382 | Pemetrexed | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
63323-0450-50 | 63323-0450 | PEMETREXED DISODIUM | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
68001-0536-41 | 68001-0536 | Pemetrexed | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | July 4, 2022 | In Use | |
68001-0539-41 | 68001-0539 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 24, 2022 | In Use | |
70710-1655-01 | 70710-1655 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 26, 2022 | In Use | |
70771-1692-01 | 70771-1692 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 26, 2022 | In Use | |
68001-0544-41 | 68001-0544 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 1, 2022 | In Use | |
70121-1233-01 | 70121-1233 | Pemetrexed | Pemetrexed disodium | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Aug. 10, 2022 | In Use |
Found 10,000 results in 14 milliseconds — Export these results